Cargando…

P1169: COMPARISON OF REAL-WORLD CLINICAL OUTCOMES IN PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA TREATED WITH EPCORITAMAB VS CHEMOIMMUNOTHERAPY

Detalles Bibliográficos
Autores principales:	Ip, Andrew, Rosenthal, Allison, Mutebi, Alex, Wang, Tongsheng, Jun, Monika, Wang, Anthony, Yu, Junhua, Brodkin, Samantha, Sacchi, Mariana, Kalsekar, Anupama, Munoz, Javier
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10431018/ http://dx.doi.org/10.1097/01.HS9.0000971572.32493.7a

Ejemplares similares

P1149: COMPARISON OF THE EFFICACY OF EPCORITAMAB VERSUS CHIMERIC ANTIGEN RECEPTOR THERAPIES, POLATUZUMAB-BASED REGIMENS, AND TAFASITAMAB-BASED REGIMENS
por: Rosenthal, Allison, et al.
Publicado: (2023)

P1176: CLINICAL OUTCOMES OF NOVEL THERAPIES IN RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
por: Crombie, Jennifer, et al.
Publicado: (2023)

Systematic review of outcomes and patient heterogeneity in relapsed or refractory diffuse large B-cell lymphoma
por: Miller, Sally D, et al.
Publicado: (2022)

P1135: SUBCUTANEOUS EPCORITAMAB IN COMBINATION WITH RITXUIMAB + LENALIDOMIDE IN RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA: PHASE 1/2 TRIAL UPDATE
por: Belada, D., et al.
Publicado: (2022)

P1154: EFFICACY OF SUBCUTANEOUS EPCORITAMAB VS AXI-CEL IN R/R DLBCL CAR T-NAIVE AND CAR T-ELIGIBLE PATIENTS: AN INDIRECT COMPARISON
por: Thieblemont, Catherine, et al.
Publicado: (2023)

P1118: LONGER FOLLOW-UP FROM THE PIVOTAL EPCORE NHL-1 TRIAL REAFFIRMS SUBCUTANEOUS EPCORITAMAB INDUCES DEEP, DURABLE COMPLETE REMISSIONS IN PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA
por: Jurczak, Wojciech, et al.
Publicado: (2023)

Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell–Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial
por: Thieblemont, Catherine, et al.
Publicado: (2023)

P1213: SUBCUTANEOUS EPCORITAMAB WITH GEMOX INDUCED HIGH RESPONSE RATES IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA INELIGIBLE FOR AUTOLOGOUS STEM CELL TRANSPLANT
por: Wahlin, B. E., et al.
Publicado: (2022)

1169 ejercicios y juegos de atletismo
por: Olivera Betrán, Javier
Publicado: (1995)

1169 ejercicios y juegos de atletismo
por: Olivera Betrán, Javier
Publicado: (1997)

Chemoimmunotherapy with brentuximab vedotin combined with ifosfamide, gemcitabine, and vinorelbine is highly active in relapsed or refractory classical Hodgkin lymphoma
por: Abuelgasim, Khadega A., et al.
Publicado: (2019)

P1215: PRELIMINARY PHASE 1/2 RESULTS OF SUBCUTANEOUS EPCORITAMAB + R-DHAX/C IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA ELIGIBLE FOR AUTOLOGOUS STEM CELL TRANSPLANT
por: Cordoba, R., et al.
Publicado: (2022)

Relapsed/Refractory Chronic Lymphocytic Leukemia: Chemoimmunotherapy, Treatment until Progression with Mechanism-Driven Agents or Finite-Duration Therapy?
por: Cuneo, Antonio, et al.
Publicado: (2019)

Food Labelling: A Brief Analysis of European Regulation 1169/2011
por: Fransvea, Armida, et al.
Publicado: (2014)

Primary testicular lymphoma: A SEER analysis of 1,169 cases
por: Xu, Haitao, et al.
Publicado: (2019)

Epcoritamab-bysp (Epkinly) – A phenomenal breakthrough in the treatment of diffuse large B-cell lymphoma
por: Riaz, Rumaisa, et al.
Publicado: (2023)

KIR/KIR-ligand genotypes and clinical outcomes following chemoimmunotherapy in patients with relapsed or refractory neuroblastoma: a report from the Children’s Oncology Group
por: Erbe, Amy K, et al.
Publicado: (2023)

1169. In Vitro Activity of Posaconazole versus Voriconazole for the Treatment of Invasive Aspergillosis in Adults Enrolled in a Clinical Trial
por: Castanheira, Mariana, et al.
Publicado: (2020)

Phase Ib/II study of safety and efficacy of low‐dose decitabine‐primed chemoimmunotherapy in patients with drug‐resistant relapsed/refractory alimentary tract cancer
por: Chen, Meixia, et al.
Publicado: (2018)

1169. Preventing Central Line-Associated Bloodstream Infections in Long-Term Acute Care
por: Jacob, Jerry, et al.
Publicado: (2019)

1169. Derivation And Validation of an International Clinical Prognostication Model for 28-day Sepsis Mortality.
por: Blair, Paul W, et al.
Publicado: (2022)

Semimechanistic Physiologically‐Based Pharmacokinetic/Pharmacodynamic Model Informing Epcoritamab Dose Selection for Patients With B‐Cell Lymphomas
por: Li, Tommy, et al.
Publicado: (2022)

What Influences the Choice of Ibrutinib–Rituximab vs Classic Chemoimmunotherapy for Chronic Lymphocytic Leukemia?
por: Bravaccini, Sara, et al.
Publicado: (2020)

Defining drug/drug class refractoriness vs lines of therapy in relapsed/refractory multiple myeloma
por: Goel, Utkarsh, et al.
Publicado: (2023)

Cytotoxicity of the CD3×CD20 bispecific antibody epcoritamab in CLL is increased by concurrent BTK or BCL-2 targeting
por: Mhibik, Maissa, et al.
Publicado: (2023)

Risk Factors for Osteochondral Lesions and Osteophytes in Chronic Lateral Ankle Instability: A Case Series of 1169 Patients
por: Wang, Ding-yu, et al.
Publicado: (2020)

1169. Surveillance of Antibiotic-Resistant Bacteria Reported Among Healthcare-Associated Infections, California, 2011–2017
por: Rizzo, Kyle, et al.
Publicado: (2018)

Low-Dose Decitabine-Based Chemoimmunotherapy for Patients with Refractory Advanced Solid Tumors: A Phase I/II Report
por: Fan, Hui, et al.
Publicado: (2014)

Targeted delivery of liposomal chemoimmunotherapy for cancer treatment
por: Liu, Yusheng, et al.
Publicado: (2022)

Advances in Lipid-Based Nanoparticles for Cancer Chemoimmunotherapy
por: Wang, Tianqi, et al.
Publicado: (2021)

Potential Prognostic Markers for Relapsed/Refractory vs. Responsive Acute Myeloid Leukemia
por: Vitkevičienė, Aida, et al.
Publicado: (2022)

Efficacy comparison of tisagenlecleucel vs usual care in patients with relapsed or refractory follicular lymphoma
por: Salles, Gilles, et al.
Publicado: (2022)

MAPK signaling regulates the efficacy of chemoimmunotherapy
por: Ghiringhelli, François
Publicado: (2022)

S222: EPCORITAMAB WITH RITUXIMAB + LENALIDOMIDE (R2) PROVIDES DURABLE RESPONSES IN PATIENTS WITH HIGH-RISK FOLLICULAR LYMPHOMA, REGARDLESS OF POD24 STATUS
por: Sureda, Anna, et al.
Publicado: (2023)

Trispecific natural killer cell nanoengagers for targeted chemoimmunotherapy
por: Au, Kin Man, et al.
Publicado: (2020)

Reduced-Intensity Anthracycline-Free Chemoimmunotherapy in Elderly Patients With Newly Diagnosed or Relapsed Diffuse Large B-Cell Lymphoma
por: Yohannan, Binoy, et al.
Publicado: (2023)

Blinatumomab vs historical standard therapy of adult relapsed/refractory acute lymphoblastic leukemia
por: Gökbuget, N, et al.
Publicado: (2016)

Bortezomib plus dexamethasone vs thalidomide plus dexamethasone for relapsed or refractory multiple myeloma
por: Iida, Shinsuke, et al.
Publicado: (2018)

1169. Revenge of the Syph(ilis): Investigating Congenital Syphilis at a Tertiary Care Center Amidst a Rising Epidemic
por: Ness, Tara, et al.
Publicado: (2021)

Cost-effectiveness of targeted treatment vs chemoimmunotherapy in treatment-naive unfit CLL without TP53 aberrations
por: Slot, Matilde, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_gsbkiahfnmavjkdr58l6p0dn39